Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?

@article{Giovannoni2005NeutralizingAA,
  title={Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?},
  author={Gavin Giovannoni and Andrew Marc Goodman},
  journal={Neurology},
  year={2005},
  volume={65 1},
  pages={
          6-8
        }
}
Neutralizing antibodies (NAbs) are a major hurdle to the successful use of biologics in clinical practice. The impact of NAbs is obvious in biologic systems with no redundancy. NAbs induced in response to treatment with recombinant erythropoietin or thrombopoietin cause life-threatening complications of pure red cell aplasia and thrombocytopenia as a direct result of inhibiting the activity of the endogenous hormones. For the type 1 interferons (α and β), NAbs have not yet been shown to have… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

[Diagnosis and treatment of multiple sclerosis].

  • Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
  • 2011

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES